NCT01908192 — Schizophrenia trial site landscape

Public-registry site landscape for NCT01908192, “Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®”, a Schizophrenia study sponsored by SyneuRx International (Taiwan) Corp. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT01908192 (registry record)
Study title	Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
Official title	An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents
Sponsor	SyneuRx International (Taiwan) Corp
Condition(s)	Schizophrenia
Phase	PHASE2 / PHASE3
Listed sites	23
Site countries	United States, Taiwan

Patient-friendly overview of this study: eichor.com/study/NCT01908192.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT01908192 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →